Written by Luc Geeraert and the CAM-Cancer Consortium.
Updated June 29, 2017

Insulin potentiation therapy

Does it work?

IPT inventor Perez and his successors claimed that several cancer patients were successfully treated with IPT 1,3, though case reports or clinical trials to substantiate these claims have never been published in peer-reviewed journals.

More recently, two small clinical studies and four cases have been published in peer-reviewed journals.

Clinical trials

In a small uncontrolled study 4, 16 patients with castration-resistant tumours were treated with insulin (0.4 units per kg body weight at 5-day intervals) in combination with goserelin depot (3.6 mg) and low-dose chemotherapy, i.e., eight patients with: cyclophosphamide (0.10–0.15 g/m2) + epirubicin (3 mg/m2) + vinblastine (0.5 mg/m2), and eight patients with docetaxel (3.6 mg/m2). Overall prostate-specific antigen (PSA) results after the sixth course of IPT showed partial effect in eight patients, stabilization in four patients, and disease progression in four patients; the median survival for all treated patients was 11.7 months. During the treatment no significant side effects were observed, and no lethal cases occurred.

In a small prospective, controlled, randomized clinical trial 5, IPT was tested in 30 women suffering from metastatic breast cancer resistant to 5-fluorouracil + doxorubicin + cyclophosphamide and to hormone therapy with measurable lesions 4. Patients were divided in three groups of ten: a group receiving only the anticancer drug methotrexate (2.5 mg/m2 every other day), a group receiving only insulin (0.3 units per kg body weight every other day), and a group receiving a combination of both. Drugs were given in two 3-week courses with a 1-week interval in-between. After 8 weeks, the sizes of the target tumours were measured and compared to the respective sizes before treatment. Progressive disease was less frequently observed in the group treated with the combination of methotrexate and insulin, and in this group the median increase in tumour size was found to be significantly lower than in the groups where drugs were used separately. Quality of life, patient survival, or lasting effects were not evaluated.

Case studies

Three cases of IPT in patients with advanced metastatic cancer and failure of preceding standard conventional treatment have been described: two women with breast cancer, and one man with prostate cancer 13. The initial 4 to 6 IPT courses (insulin + patient-specific chemotherapy) were repeated weekly after which a maintenance schedule at several-week intervals was started. The treatment was well tolerated. Laboratory examinations showed no significant toxicity. Remission was achieved for 15 months (after which the patient was lost to follow up), and 21 and 8 months (publication time of results).

In another case study, a woman with breast cancer was treated with IPT 14. Treatment (insulin + chemotherapy) was repeated twice-weekly for 3 weeks, and then weekly for 5 weeks. After 8 weeks, the breast mass was no longer palpable, and no evidence of tumour was found on a xeromammogram at 3 months.

Pre-clinical trials

Tumour-bearing rats were found to have a significantly more reduced tumour size after treatment with doxorubicin (one single dose) and insulin (once-daily, starting 1 day after doxorubicin administration) than after being treated with doxorubicin alone 15. Insulin also led to a marked improvement in food intake and host weight.

In several human cancer cell lines, insulin enhanced the cytotoxic effect of chemotherapeutics 16-19. Testing a broad range of human tumours 20, insulin increased significantly the colony formation in about half of the tested tumour cells, but only little difference in the sensitivity to cytotoxic agents was observed.

Citation Luc Geeraert, CAM-Cancer Consortium. Insulin potentiation therapy [online document]. http://ws.cam-cancer.org/The-Summaries/Dietary-approaches/Insulin-potentiation-therapy. June 29, 2017.


  1. Ayre SG, Perez Garcia y Bellon D, Perez Garcia D Jr. Insulin potentiation therapy: a new concept in the management of chronic degenerative disease. Med. Hypotheses. 1986 Jun;20(2):199-210.
  2. Joshi SR, Parikh RM, Das AK. Insulin--history, biochemistry, physiology and pharmacology. J. Assoc. Physicians India. 2007 Jul;55 Suppl:19-25.
  3. Ayre SG, Garcia y Bellon DP, Garcia DP Jr. Insulin, chemotherapy, and the mechanisms of malignancy: the design and the demise of cancer. Med. Hypotheses. 2000 Oct;55(4):330-334.
  4. Damyanov C, Gerasimova D, Maslev I, Gavrilov V. Low-dose chemotherapy with insulin (insulin potentiation therapy) in combination with hormone therapy for treatment of castration-resistant prostate cancer. ISRN Urol. 2012;2012:140182.
  5. Lasalvia-Prisco E, Cucchi S, Vázquez J, Lasalvia-Galante E, Golomar W, Gordon W. Insulin-induced enhancement of antitumoral response to methotrexate in breast cancer patients. Cancer Chemother. Pharmacol. 2004 Mar;53(3):220-224.
  6. Murray I. Paulesco and the isolation of insulin. J. Hist. Med. Allied Sci. 1971 Apr;26(2):150-157.
  7. Bliss M. The history of insulin. Diabetes Care. 1993 Dec;16 Suppl 3:4-7.
  8. De Meyts P. Insulin and its receptor: structure, function and evolution. Bioessays. 2004 Dec;26(12):1351-1362.
  9. Sandow J. Growth effects of insulin and insulin analogues. Arch. Physiol. Biochem. 2009 May;115(2):72-85.
  10. Straus DS. Growth-stimulatory actions of insulin in vitro and in vivo. Endocr. Rev. 1984 Spring;5(2):356-369.
  11. Arizona Center for Advanced Medicine. Frequently Asked Questions About IPTLD [online document]. Available from http://arizonaadvancedmedicine.com/therapies/IPT_therapy.html, last accessed 29th June 2017.
  12. Baratz R, Why you should stay away from insulin potentiation therapy.Quackwatch.org [Internet]. August 2013. Available from http://www.quackwatch.org/01QuackeryRelatedTopics/Cancer/ipt.html, last accessed 29th June 2017.
  13. Damyanov C, Radoslavova M, Gavrilov V, Stoeva D. Low dose chemotherapy in combination with insulin for the treatment of advanced metastatic tumors. Preliminary experience. J. BUON. 2009 14(4):711–715.
  14. Ayre SG, Perez Garcia y Bellon D, Perez Garcia D Jr. Neoadjuvant low-dose chemotherapy with insulin in breast carcinomas. Eur. J. Cancer. 1990;26(11-12):1262-1263.
  15. Peacock JL, Gorschboth CM, Norton JA. Impact of insulin on doxorubicin-induced rat host toxicity and tumor regression. Cancer Res. 1987 Aug 15;47(16):4318-4322.
  16. Oster JB, Creasey WA. Enhancement of cellular uptake of ellipticine by insulin preincubation. Eur. J. Cancer Clin. Oncol. 1981 Oct;17(10):1097-1103.
  17. Alabaster O, Vonderhaar BK, Shafie SM. Metabolic modification by insulin enhances methotrexate cytotoxicity in MCF-7 human breast cancer cells. Eur. J. Cancer Clin. Oncol. 1981 Nov;17(11):1223-1228.
  18. Jiao SC, Huang J, Sun Y, Lu SX. [The effect of insulin on chemotherapeutic drug sensitivity in human esophageal and lung cancer cells]. [Article in Chinese]. Zhonghua Yi Xue Za Zhi. 2003 Feb 10;83(3):195-197.
  19. Zou K, Ju JH, Xie H. Pretreatment with insulin enhances anticancer functions of 5-fluorouracil in human esophageal and colonic cancer cells. Acta Pharmacol. Sin. 2007 May;28(5):721-730.
  20. Kern DH, Chien FW, Morton DL. Selective effects of insulin and hydrocortisone on colony formation and chemosensitivity of human tumors in soft agar. Int. J. Cancer. 1984 Jun 15;33(6):807-812.
  21. Memorial Sloan Kettering Cancer Center. Insulin Potentiation Therapy [online document]. Available from: https://www.mskcc.org/cancer-care/integrative-medicine/herbs/insulin-potentiation-therapy#field-herb-drug-interactions, last accessed 29th June 2017 .
  22. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. CA Cancer J. Clin. 2010 July-August;60(4):207-221.
  23. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr. Relat. Cancer. 2009 December;16(4):1103-1123.
  24. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J. Clin. Oncol. 2002 January 1;20(1):42-51.
  25. Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J. Clin. Oncol. 2009 Jan 10;27(2):176-185.